GILEAD SCIENCES (GIS HM) stock market data APIs
€94.6234
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.HM.
Prev. Close
94.6234
Open
94.6234
High
94.6234
Low
94.6234
52 wk Range
71.8253-108.617
Market Cap
78 028 M
Dividends (Yield)
0.0266
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
Fangzhou Inc. SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Awa...
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Gilead Sciences (GILD) closed at $112.26 in the latest trading session, marking a +1.26% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.1% for the day. Elsewhere...
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics, Inc. Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are bein...
Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best drug stocks to buy right now. In a report released on September 12, Simon Baker CFA from Redburn Atlantic maintained a Buy rating on Gilead Scien...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
